作者: Lauren Hammock , Melinda Lewis , Carol Phillips , Cynthia Cohen
DOI: 10.1053/S0046-8177(03)00409-X
关键词:
摘要: Breast cancer patients with HER-2/neu oncogene amplification by fluorescence in situ hybridization (FISH) have been shown to a better response trastuzumab (Herceptin) therapy than those showing protein overexpression only. Many centers currently perform FISH only on tumors 2+ positivity immunohistochemistry (IHC), the assumption that 3+ virtually equates amplification. Results of performed 102 breast cases over 12-month period were correlated IHC results. was using ratio and chromosome 17 centromere signal counts (PathVysion; Vysis, Downers Grove, IL). Immunohistochemical expression evaluated according published scoring guidelines HercepTest (Dako, Carpinteria, CA). Only 22 45 (49%) showed FISH. 2 25 staining (6%) gene amplification, 1 negative (4%) weak Of (88%) positivity, (8%) IHC. More 50% strong do not show Most also fail amplify. In our experience, studies should be all avoid inappropriate toxic treatment. The decision IHC-negative guided additional parameters, including tumor grade estrogen receptor status.